Table 3.

Comparison of human lymphoproliferative and chemotactic responses to S-Ag peptide fragments

Human peptide/protein	Peptide sequence	Lymphoproliferative response in patients*	Lymphoproliferative response in controls	Chemotaxis
S-Ag	—	±	±	+
1-20	MAASGKTSKSEPNHVIFKKI	—	—	+
11-30	EPNHVIFKKISRDKSVTIYL	±	—	+
41-60	QVQPVDGVVLVDPDLVKGKK	—	—	+
121-140	PFLLTFPDYLPCSVMLQPAP	+	+	+
131-150	PCSVMLQPAPQDSGKSCGVD	±†	—	+
141-160	QDSGKSCGVDFEVKAFATDS	—	—	—
151-170	FEVKAFATDSTDAEEDKIPK	—	—	—
161-180	TDAEEDKIPKKSSVRYLIRS	±‡	—	—
171-190	KSSVRYLIRSVQHAPLEMGP	±‡	—	—
IRBP	—	±	—	+

Data compiled from de Smet et al.³,¹⁷

± indicates 25%-49% of individuals showed a 2-fold increase in lymphocyte proliferation to ≥ 50 μg/mL of peptide or protein; —, no response observed; and +, 50% or more individuals showed a 2-fold increase in lymphocyte proliferation to ≥ 50 μg/mL of peptide or protein.

^*Individuals diagnosed with Behçet disease, sarcoidosis, or Vogt Koyanagi Harada disease

^†Individuals diagnosed with Behçet disease, sarcoidosis only

^‡Individuals diagnosed with Behçet disease only